Jeffrey Hrkach 1 , Daniel Von Hoff , Mir Mukkaram Ali , Elizaveta Andrianova , Jason Auer , Tarikh Campbell , David De Witt , Michael Figa , Maria Figueiredo , Allen Horhota , Susan Low , Kevin McDonnell , Erick Peeke , Beadle Retnarajan , Abhimanyu Sabnis , Edward Schnipper , Jeffrey J Song , Young Ho Song , Jason Summa , Douglas Tompsett , Greg Troiano , Tina Van Geen Hoven , Jim Wright , Patricia LoRusso , Philip W Kantoff , Neil H Bander , Christopher Sweeney , Omid C Farokhzad , Robert Langer , Stephen Zale
Apr 4 2012
We describe the development and clinical translation of a targeted polymeric nanoparticle (TNP) containing the chemotherapeutic docetaxel (DTXL) for the treatment of patients with solid tumors. DTXL-TNP is targeted to prostate-specific membrane antigen, a clinically validated tumor antigen expressed on prostate cancer cells and on the neovasculature of most nonprostate solid tumors. DTXL-TNP was developed from a combinatorial library of more than 100 TNP formulations varying with respect to particle size, targeting ligand density, surface hydrophilicity, drug loading, and drug release properties. Pharmacokinetic and tissue distribution studies in rats showed that the NPs had a blood circulation half-life of about 20 hours and minimal liver accumulation. In tumor-bearing mice, DTXL-TNP exhibited markedly enhanced tumor accumulation at 12 hours and prolonged tumor growth suppression compared to a solvent-based DTXL formulation (sb-DTXL). In tumor-bearing mice, rats, and nonhuman primates, DTXL-TNP displayed pharmacokinetic characteristics consistent with prolonged circulation of NPs in the vascular compartment and controlled release of DTXL, with total DTXL plasma concentrations remaining at least 100-fold higher than sb-DTXL for more than 24 hours. Finally, initial clinical data in patients with advanced solid tumors indicated that DTXL-TNP displays a pharmacological profile differentiated from sb-DTXL, including pharmacokinetics characteristics consistent with preclinical data and cases of tumor shrinkage at doses below the sb-DTXL dose typically used in the clinic.